Feed RXRX
RX

Recursion Pharmaceuticals

RXRX · NASDAQ

$3.89 +6.58% (+$0.24)
1M +11.46%
Market Cap $2.04B
P/E Ratio -
Div. Yield -
ROE 50.41%
Piotroski F-Score Weak
3/9
Valuation
41 /100
Fair
P/B 2.23x
P/S 37.21x
EV/FFO N/A
Growth
100 /100
Growing
Book val. growth 32.53%
Rev. growth 23.46%
FCF growth N/A
Profitability
0 /100
Weak
Net margin 945.92%
Op. margin 991.72%
FCF margin 645.82%
Quality
1 /100
Poor
ROE 50.41%
ROA 42.79%
Asset turnover 0.05x
Debt
69 /100
Low
Current ratio 5.03x
Int. coverage -350.41x
Debt/Equity 0.07x
Stability
75 /100
Stable
Rev. volatility 12.06%
EPS volatility 15.90%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about RXRX
Online

About the company

Recursion Pharmaceuticals is a biotechnology company that utilizes modern technologies such as artificial intelligence and machine learning to discover new therapeutic compounds and potential treatment approaches.

The key element of their approach is the use of image processing and data analysis systems to create comprehensive maps of cellular processes. This aims to identify potential targets for drugs and therapeutic substances in the fields of genetics, cellular biology, and diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Najat Khan

Employees

600

Headquarters

Salt Lake City

Upcoming events

04 NOV

Earnings

Upcoming earnings report

40d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.